Novus Therapeutics acquires Anelixis Therapeutics

By The Science Advisory Board staff writers

September 15, 2020 -- Novus Therapeutics has completed the acquisition of Anelixis Therapeutics, including the lead clinical-stage compound AT-1501, a next-generation anti-CD40L antibody for the treatment of organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.

Novus has also completed private placement funding of $108 million that will be used to fund operations including the advancement of AT-1501 to phase II clinical trials in renal transplantation, islet cell transplantation, autoimmune nephritis, and amyotrophic lateral sclerosis (ALS).

A previous phase I clinical safety study demonstrated that AT-1501 was well-tolerated at all doses tested in healthy volunteers and patients with ALS.

New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that...
AbbVie, I-Mab partner on cancer mAb, I-Mab raises $418M
AbbVie and I-Mab have signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal...
Kite submits BLA for CAR T in non-Hodgkin lymphomas
Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel...
MD Anderson, Xencor partner on XmAb candidates
The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together,...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter